212 related articles for article (PubMed ID: 35115556)
1. Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.
Yan Y; Zhou B; Qian C; Vasquez A; Kamra M; Chatterjee A; Lee YJ; Yuan X; Ellis L; Di Vizio D; Posadas EM; Kyprianou N; Knudsen BS; Shah K; Murali R; Gertych A; You S; Freeman MR; Yang W
Nat Commun; 2022 Feb; 13(1):669. PubMed ID: 35115556
[TBL] [Abstract][Full Text] [Related]
2. Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation.
Jiao J; Ruan L; Cheng CS; Wang F; Yang P; Chen Z
Mol Med; 2023 Apr; 29(1):47. PubMed ID: 37016317
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.
Canning P; Ruan Q; Schwerd T; Hrdinka M; Maki JL; Saleh D; Suebsuwong C; Ray S; Brennan PE; Cuny GD; Uhlig HH; Gyrd-Hansen M; Degterev A; Bullock AN
Chem Biol; 2015 Sep; 22(9):1174-84. PubMed ID: 26320862
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling.
Hrdinka M; Schlicher L; Dai B; Pinkas DM; Bufton JC; Picaud S; Ward JA; Rogers C; Suebsuwong C; Nikhar S; Cuny GD; Huber KV; Filippakopoulos P; Bullock AN; Degterev A; Gyrd-Hansen M
EMBO J; 2018 Sep; 37(17):. PubMed ID: 30026309
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib Inhibits Invasion and Metastasis of Osteosarcoma via Inhibition of Macrophage Receptor Interacting Serine-Threonine Kinase 2.
Maloney C; Kallis MP; Edelman M; Tzanavaris C; Lesser M; Soffer SZ; Symons M; Steinberg BM
Mol Cancer Ther; 2020 Jun; 19(6):1340-1350. PubMed ID: 32371577
[TBL] [Abstract][Full Text] [Related]
6.
Umbreen S; Banday MM; Jamroze A; Mansini AP; Ganaie AA; Ferrari MG; Maqbool R; Beigh FH; Murugan P; Morrissey C; Corey E; Konety BR; Saleem M
Mol Cancer Ther; 2019 Nov; 18(11):2111-2123. PubMed ID: 31467179
[TBL] [Abstract][Full Text] [Related]
7. The potent and selective RIPK2 inhibitor BI 706039 improves intestinal inflammation in the TRUC mouse model of inflammatory bowel disease.
Ermann J; Matmusaev M; Haley EK; Braun C; Jost F; Mayer-Wrangowski S; Hsiao P; Ting N; Li L; Terenzio D; Chime J; Lukas S; Patnaude L; Panzenbeck M; Csordas D; Zheng J; Mierz D; Simpson T; King FJ; Klimowicz AP; Mbow ML; Fine JS; Miller CA; Fogal SE; Byrne FR
Am J Physiol Gastrointest Liver Physiol; 2021 Nov; 321(5):G500-G512. PubMed ID: 34494462
[TBL] [Abstract][Full Text] [Related]
8. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Vatapalli R; Sagar V; Rodriguez Y; Zhao JC; Unno K; Pamarthy S; Lysy B; Anker J; Han H; Yoo YA; Truica M; Chalmers ZR; Giles F; Yu J; Chakravarti D; Carneiro B; Abdulkadir SA
Nat Commun; 2020 Aug; 11(1):4153. PubMed ID: 32814769
[TBL] [Abstract][Full Text] [Related]
9. Disruption of the c-Myc/miR-200b-3p/PRDX2 regulatory loop enhances tumor metastasis and chemotherapeutic resistance in colorectal cancer.
Lv Z; Wei J; You W; Wang R; Shang J; Xiong Y; Yang H; Yang X; Fu Z
J Transl Med; 2017 Dec; 15(1):257. PubMed ID: 29258530
[TBL] [Abstract][Full Text] [Related]
10. MAGE-C2/CT10 promotes growth and metastasis through upregulating c-Myc expression in prostate cancer.
Qiu J; Yang B
Mol Cell Biochem; 2021 Jan; 476(1):1-10. PubMed ID: 32935296
[TBL] [Abstract][Full Text] [Related]
11. Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation.
Faskhoudi MA; Molaei P; Sadrkhanloo M; Orouei S; Hashemi M; Bokaie S; Rashidi M; Entezari M; Zarrabi A; Hushmandi K; Mirzaei S; Gholami MH
Pathol Res Pract; 2022 May; 233():153851. PubMed ID: 35339914
[TBL] [Abstract][Full Text] [Related]
12. SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-Myc in prostate cancer.
Li X; Wu JB; Li Q; Shigemura K; Chung LW; Huang WC
Oncotarget; 2016 Mar; 7(11):12869-84. PubMed ID: 26883200
[TBL] [Abstract][Full Text] [Related]
13. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
15. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease.
Tigno-Aranjuez JT; Benderitter P; Rombouts F; Deroose F; Bai X; Mattioli B; Cominelli F; Pizarro TT; Hoflack J; Abbott DW
J Biol Chem; 2014 Oct; 289(43):29651-64. PubMed ID: 25213858
[TBL] [Abstract][Full Text] [Related]
16. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
17. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.
Lee JK; Phillips JW; Smith BA; Park JW; Stoyanova T; McCaffrey EF; Baertsch R; Sokolov A; Meyerowitz JG; Mathis C; Cheng D; Stuart JM; Shokat KM; Gustafson WC; Huang J; Witte ON
Cancer Cell; 2016 Apr; 29(4):536-547. PubMed ID: 27050099
[TBL] [Abstract][Full Text] [Related]
18. R1 Regulates Prostate Tumor Growth and Progression By Transcriptional Suppression of the E3 Ligase HUWE1 to Stabilize c-Myc.
Lin TP; Li J; Li Q; Li X; Liu C; Zeng N; Huang JM; Chu GC; Lin CH; Zhau HE; Chung LWK; Wu BJ; Shih JC
Mol Cancer Res; 2018 Dec; 16(12):1940-1951. PubMed ID: 30042175
[TBL] [Abstract][Full Text] [Related]
19. RIPK2 promotes the progression of colon cancer by regulating BIRC3-mediated ubiquitination of IKBKG.
Zhang Z; Pan Y; Zhao Y; Ren M; Li Y; Lu G; He S
Exp Cell Res; 2023 Aug; 429(1):113644. PubMed ID: 37211186
[TBL] [Abstract][Full Text] [Related]
20. IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling.
Sheng X; Nenseth HZ; Qu S; Kuzu OF; Frahnow T; Simon L; Greene S; Zeng Q; Fazli L; Rennie PS; Mills IG; Danielsen H; Theis F; Patterson JB; Jin Y; Saatcioglu F
Nat Commun; 2019 Jan; 10(1):323. PubMed ID: 30679434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
